Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.80 |
| ▸ | HRH1 | P35367 | 9/20 | 0.80 |
| ▸ | HTR2C | P28335 | 9/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242539 | 0.90 | HTR2C (0.78) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL23242553 | 0.89 | HTR2A (1.00) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL23242500 | 0.89 | HTR2A (0.80) | HTR2AHRH1HTR2C | |
| SCHEMBL23242538 | 0.83 | HTR2C (0.86) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL23242502 | 0.82 | HTR2C (1.00) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL10194037 | 0.81 | HTR2C (0.79) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL14198346 | 0.79 | HRH4 (0.67) | HTR2AHRH1HTR2CDRD2DRD1 | |
| SCHEMBL23242516 | 0.79 | HTR2A (0.64) | HTR2AHRH1HTR2C | |
| SCHEMBL31208379 | 0.79 | HTR2A (0.64) | HTR2AHRH1HTR2C | |
| SCHEMBL23242517 | 0.78 | HTR2A (0.79) | HTR2AHRH1HTR2CDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HRH1 30/4885HTR2C 3/4885 |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HRH1 30/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.